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Background: Reducing low-density lipoprotein cholesterol (LDL-C) is associated with reduced risk for major
coronary events. Despite statin efficacy, a considerable proportion of statin-treated hypercholesterolemic patients fail
to reach therapeutic LDL-C targets as defined by guidelines. This study compared the efficacy of ezetimibe added
to ongoing statins with doubling the dose of ongoing statin in a population of Taiwanese patients with
hypercholesterolemia.
Methods: This was a randomized, open-label, parallel-group comparison study of ezetimibe 10 mg added to
ongoing statin compared with doubling the dose of ongoing statin. Adult Taiwanese hypercholesterolemic patients
not at optimal LDL-C levels with previous statin treatment were randomized (N = 83) to ongoing statin + ezetimibe
(simvastatin, atorvastatin or pravastatin + ezetimibe at doses of 20/10, 10/10 or 20/10 mg) or doubling the dose of
ongoing statin (simvastatin 40 mg, atorvastatin 20 mg or pravastatin 40 mg) for 8 weeks. Percent change in total
cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides, and specified safety parameters
were assessed at 4 and 8 weeks.
Results: At 8 weeks, patients treated with statin + ezetimibe experienced significantly greater reductions compared
with doubling the statin dose in LDL-C (26.2% vs 17.9%, p = 0.0026) and total cholesterol (20.8% vs 12.2%, p = 0.0003).
Percentage of patients achieving treatment goal was greater for statin + ezetimibe (58.6%) vs doubling statin (41.2%),
but the difference was not statistically significant (p = 0.1675). The safety and tolerability profiles were similar between
treatments.
Conclusion: Ezetimibe added to ongoing statin therapy resulted in significantly greater lipid-lowering compared with
doubling the dose of statin in Taiwanese patients with hypercholesterolemia. Studies to assess clinical outcome benefit
are ongoing.
Trial registration: Registered at ClinicalTrials.gov: NCT00652327
Keywords: Ezetimibe, Simvastatin, Atorvastatin, Pravastatin* Correspondence: jueyhwang@ntu.edu.tw
6Cardiovascular Division, Department of Internal Medicine, National Taiwan
University College of Medicine and Hospital, Taipei, Taiwan
Full list of author information is available at the end of the article
© 2012 Yu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Yu et al. BMC Research Notes 2012, 5:251 Page 2 of 8
http://www.biomedcentral.com/1756-0500/5/251Background
Chinese populations are perceived to have lower low-
density lipoprotein cholesterol (LDL-C) levels and coron-
ary heart disease (CHD) risk than Caucasians [1]. How-
ever, as life expectancy and the standard of living
improve in Asian countries, an increased risk for cardio-
vascular disease, high blood pressure, diabetes and dysli-
pidemia have become more prevalent and are predicted
to continue to rise as the population ages [2]. LDL-C is
the primary target of cholesterol-lowering therapy. Redu-
cing serum levels of LDL-C is associated with a reduc-
tion in risk for major coronary events [3-9] and greater
reduction in ischemic heart disease [10].
The National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III), American Heart
Association/American College of Cardiology (AHA/ACC)
and European Society of Cardiology (ESC) guidelines rec-
ommend therapeutic life changes (TLCs) as the first line
of treatment; and in patients who do not meet lipid-
lowering targets with TLCs, addition of medication
may be recommended [11-13]. HMG-CoA reductase
inhibitors (statins) are the first line of therapy as an
adjunct to TLCs [14,15]. They inhibit cholesterol syn-
thesis in the liver and dose-dependent reductions in
LDL-C range from 20% to 60%, depending on the
drug and dosage used [16-21].
Despite statin efficacy, a considerable proportion of
statin-treated patients with hypercholesterolemia fail
to reach therapeutic LDL-C targets as defined by
guidelines. This may be attributed to lack of use of
adequate doses of statins, the extent of cholesterol
lowering required in some individuals, or in some
cases, safety and tolerability issues with high-dose sta-
tins. Moreover, health insurance regulations in Taiwan
may play a role in prescribing practices that impact
dosing and brand of statin [22,23]. Ezetimibe select-
ively inhibits the intestinal absorption of cholesterol
and related phytosterols. Its molecular target is the
sterol transporter, Niemann-Pick C1-like 1 (NPC1L1),
which is responsible for cholesterol absorption in the
intestine [24-30]. It has a mechanism of action that is
complementary to that of statins and has been shown
to reduce LDL-C levels significantly more than pla-
cebo (reviewed in [31]). Ezetimibe also improves other
lipids such as high-density lipoprotein cholesterol
(HDL-C), triglycerides, and Apo B (reviewed in [31]).
Statin plus ezetimibe vs comparable doses of statin
monotherapy show that coadministration is more ef-
fective than statin monotherapy at reducing LDL-C,
even at high statin doses (reviewed in [31]). Ezetimibe
has been shown to inhibit the development of athero-
sclerosis in Apo E knockout mice [32], and trials to
assess clinical outcome benefit with ezetimibe treat-
ment in humans are ongoing.The primary objective of this study was to compare
the LDL-C lowering efficacy of ezetimibe 10 mg added
to ongoing statins (simvastatin 20 mg, atorvastatin
10 mg or pravastatin 20 mg) with doubling the dose of
ongoing statin after 8 weeks of treatment in a population
of Taiwanese patients with hypercholesterolemia. Sec-
ondary objectives were to compare the effect of ezeti-
mibe 10 mg added to ongoing statins with doubling the
dose of ongoing statin with respect to effects on total
cholesterol, triglycerides and HDL-C; proportion of
patients achieving therapeutic LDL-C targets (based on
individual risk), safety and tolerability.Methods
Study design and ethics
This was a randomized, open-label, parallel-group com-
parison study conducted at 3 sites in Taiwan between
February 2006 and July 2007. The study was conducted
according to the Declaration of Helsinki and the laws/
regulations of the local health authorities as well as Good
Clinical Practice guidelines. The study protocol and
informed consent form were reviewed and approved by
the institutional review boards of the three participating
study sites (National Taiwan University Hospital-Yun Lin
Branch, Tri-Service General Hospital, and Chung-Ho
Memorial Hospital, Kaohsiung Medical University) and
all patients gave written informed consent prior to com-
mencement of any trial-related activities. At screening
patients were instructed to follow the NCEP ATP III
therapeutic lifestyle changes or similar cholesterol-
lowering diet throughout the study.Patients
Men and women 18–80 years old with hypercholesterol-
emia who were unable to achieve NCEP ATP III recom-
mended LDL-C treatment targets while taking current
statin treatment (simvastatin 20 mg, atorvastatin 10 mg
or pravastatin 20 mg alone for at least 12 weeks) were
enrolled in the study. Inclusion criteria were triglycer-
ides ≤400 mg/dL, liver transaminases (alanine amino-
transferase [ALT] and aspartate aminotransferase [AST)])
≤2 X ULN with no active liver disease, and creatine kinase
(CK) level ≤2 X ULN. Women were required to use med-
ically acceptable birth control and were excluded if they
were pregnant or lactating. Patients were excluded if they
had a history of mental illness, drug or alcohol abuse,
treatment with other investigational drugs within 3 months
of screening, active liver disease or renal impairment; un-
stable angina, uncontrolled cardiac arrhythmia, hyperten-
sion, diabetes, endocrine or metabolic disorders; or any
condition or situation, which in the opinion of the investi-
gator, might pose a risk to the patient or confound the
results of the study. In addition, patients were excluded if
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statins listed above, including fish oils, cholestin, bile-acid
sequestrants, or niacin (>200 mg/d) within 6 weeks, or
fibrates within 8 weeks of screening, or consuming
>250 mL of grapefruit juice per day. Use of prescription
and/or over-the counter-drugs with the potential for sig-
nificant lipid effects (other than study drug), or with po-
tential drug interactions with the statins were prohibited
during the study.Treatments
Patients were randomized to 1 of 2 treatments: on-
going statin plus ezetimibe (simvastatin, atorvastatin
or pravastatin plus ezetimibe at doses of 20/10, 10/10
or 20/10 mg/mg) or doubling the dose of ongoing sta-
tin (simvastatin 40 mg, atorvastatin 20 mg or pravas-
tatin 40 mg) according to their ongoing statin use. All
medications were dispensed by the study site pharma-
cies. Since this was an open-label study, there was no
blinding and no need for identity of investigational prod-
uct. Compliance was assessed at each follow-up visit by
tablet counts.Efficacy endpoints
The primary efficacy endpoint was percent change from
baseline in LDL-C after 8 weeks of treatment. Secondary
efficacy endpoints were the percent change from baseline
in total cholesterol, LDL-C, HDL-C, and triglycerides at
Week 4 and Week 8, and the proportion of patients
achieving NCEP ATP III-recommended treatment tar-
gets for LDL-C (<160 mg/dL to <100 mg/dL based on
risk stratification at baseline) [11]. Lipid assessments
were performed at a central laboratory in the National
Taiwan University Hospital Yun Lin branch. LDL-C was
calculated using the Friedewald equation. Plasma choles-
terol and triglycerides were determined using enzymatic
methods. HDL-C was measured after precipitation of the
apoprotein beta-containing lipoproteins (LDL and
VLDL) in whole plasma by heparin manganese chloride.Safety/tolerability endpoints
Adverse events were coded into COSTART preferred terms
and body systems. The occurrence of serious adverse events
or potentially dangerous abnormalities in safety tests war-
ranted patient withdrawal from medication. Laboratory
tests that were performed at baseline and at Week 8
included complete blood count, thyroid-stimulating hor-
mone (TSH), serum creatinine, total bilirubin, gamma-
glutamyl transpeptidase (GGT), ALT, AST, CK and urine
analysis. Laboratory tests that were performed at Week 4
included ALT, AST and CK. Consecutive elevations of ALT
or AST >3 X ULN were considered reason for discontinu-
ation from the study.Statistics
It was calculated that with approximately 80 subjects, 40
in each treatment group, there would be at least 85%
power to detect approximately 10% difference in the per-
centage improvement of LDL, assuming a standard devi-
ation of 15% from previous studies, alpha = 0.05, 2 sided.
The intent-to-treat (ITT) population, defined as all ran-
domized patients who took at least one dose of study
medication and had at least one post-randomization
measurement, was used for the efficacy analysis. The last
observation carried forward method was employed to ad-
just for any dropouts or missing data. Data from the 3
study centers were pooled with no adjustment for study
site. Due to the small sample size, none of the endpoints
of interest (LDL-C, total cholesterol, HDL-C, and trigly-
cerides) followed a normal distribution. Therefore, these
data were log-transformed and non-parametric methods
were used to analyze the data. The primary efficacy vari-
ables were analyzed using the Wilcoxon signed rank test to
compute the within-group differences and the Wilcoxon
rank sum test for between-group differences.
In subjects with available endpoint data, the percentage
of patients reaching prespecified treatment levels for
LDL-C between primary and secondary hypercholester-
olemia and between two treatment groups were assessed
using the Chi-square test. Median percent change from
baseline in LDL-C was assessed in patients grouped by
baseline diabetic status using descriptive statistics only
since this was a post hoc analysis and the group sizes
were small. All significance tests are two-tailed with
α= 0.05. All patients who were randomized into treat-
ment and took at least one dose of medication were
included in the safety analysis. Nonparametric methods
were used to assess between- and within-groups differ-
ences in safety parameters.
Results
The flow of participants through the study is shown in
Figure 1. Of the 202 patients screened, 83 were rando-
mized, 42 were assigned to the ezetimibe added to on-
going statin treatment group, 41 were assigned to the
double statin dose treatment group, and 20 patients had
no post-randomization LDL-C values (13 patients from
the ezetimibe group and 7 patients from the statin
group). Data from 5 subjects on statin treatment were
missing from the study and included in the ITT analysis.
Reasons for discontinuation included adverse event, 2
did not meet protocol eligibility, 1 subject did not wish
to continue for reasons unrelated to study drug and 1 for
"other" reasons. Baseline characteristics for each treat-
ment group in the ITT population are summarized in
Table 1. There were no statistically significant differences
between the treatment groups in baseline demographics,
with the exception of the mean age between the 2
Screen failure  n=119
Did not meet protocol eligibility n=115 
Lost to followup n=2 
Patient declined n=2 
No post-measurement LDL-Cvalues n=20 
          n=13 in the ezetimibe group 
          n= 7 in the statin group 





ITT population N=29 
Safety population N=42 
Doubling Statin Dose 
ITT population N=34 
Safety population N=41 
Figure 1 Dispositions of Patients.
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group and 61 years (SD= 10.6) in the statin group
(p = 0.0267).
At baseline in the ITT population, subjects in both
treatment groups showed generally similar values on
most of the laboratory tests results, except GGT and
ALT. The GGT level of the ezetimibe group at baseline







Age, mean (SD) 54.2 (10.9) 61.2 (10.5) 0.0277*
Height, mean (SD) 164.0 (10.3) 159.5 (9.2) 0.5549*
Weight, mean (SD) 75.0 (15.7) 71.0 (11.2) 0.0733*
Sex
Male, n (%) 17 (58.6) 18 (52.9) 0.7999†
Female, n (%) 12 (41.4) 16 (47.1) —
Diabetes Mellitus, n (%) 14 (48.3) 16 (47.1) 0.9304*
Hypertension, n (%) 10 (34.5) 27 (79.4) 0.0007*
Coronary Artery Disease, n (%) 8 (27.6) 10 (29.4) 0.8814*
Total cholesterol, mean (SD) 213.6 (48.4) 207.3 (28.8) 0.8577*
LDL-C, mean (SD) 144.6 (45.8) 130.9 (19.4) 0.2119*
HDL-C, mean (SD) 48.4 (9.1) 52.5 (11.9) 0.1047*
Triglycerides, mean (SD) 140.3 (59.7) 158.5 (68.1) 0.3107*
ALT, mean (SD) 30.7 (12.6) 26.9 (8.1) 0.2381*
AST, mean (SD) 25.5 (7.7) 25.2 (7.8) 0.3761*
CK, mean (SD) 121. 5 (64.0) 108.0 (77.1) 0.1924*
GGT, mean (SD) 31.8 (16.5){ 44.3 (32.0) 0.1318*
ALT Alanine aminotransferase; AST aspartate aminotransferase, CK creatine
kinase, GGT gamma-glutamyl transpeptidase; SD standard deviation.
*Wilcoxon rank sum test.
†Chi-square test.
{There was one subject in the ezetimibe group with no record for
gamma-glutamyl transpeptidase.ALT value of the ezetimibe group was numerically higher
than that of the statin group (30.7 versus 26.9;
p = 0.2381). Baseline lipid values were similar between
groups; although LDL-C was numerically higher in the
ezetimibe group vs the statin group and triglycerides
were numerically higher in the statin group (Table 1).
Median percent change from baseline and between-
treatments difference at Week 8 in LDL-C and other
lipids is shown in Figure 2. The addition of ezetimibe to
ongoing statin therapy resulted in a significantly greater
reduction from baseline in LDL-C levels compared
with doubling the ongoing statin dose after 8 weeks
of treatment (−26.2% vs −17.9%, p = 0.0026). The per-
cent change from baseline for LDL-C at Week 4 was
numerically higher for the ezetimibe group compared
with the statin group, although the difference was not
statistically significant (−21.9% vs −17.4%; p = 0.0645).
There were significantly greater reductions with ezeti-
mibe added to ongoing statin in total cholesterol at
Week 4 (−19.2% vs −12.9%; p = 0.0068) and Week 8
(−20.8% vs −12.2%; p = 0.0003). There were no signifi-
cant differences between treatments in the change
from baseline in HDL-C at Week 4 (−3.7% vs −11.3%;
p = 0.5371) or Week 8 (−5.6% vs 4.9%; p = 0.1274) nor
triglycerides at Week 4 (1.8% vs 0.7%; p = 0.8529) or
Week 8 (1.9% vs −13.1%; p = 0.4552). The number of
patients reaching LDL-C treatment goals (determined
by individual risk at randomization) after 8 weeks of
treatment was greater in the combination treatment
group, although there was no statistically significant
difference between the treatment groups in the per-
cent of patients attaining goals (p = 0.1675). A total of
17/29 (58.6%) patients taking ezetimibe added to on-
going statin attained LDL-C goal levels after 8 weeks
of treatment and a total of 14/34 (41.2%) patients re-
ceiving double their baseline statin dose attained



































Figure 2 Percent change from baseline in lipid levels after 8 weeks of treatment (ITT population).
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levels in individual patients after 8 weeks of treatment.
At baseline there was a wider range of LDL-C levels in
patients who were randomized to the ezetimibe group
(101 – 338 mg/dL) compared with those in the statin
group (101 – 174 mg/dL). After 8 weeks, the range of
LDL-C levels was nearly identical between the two treat-
ment groups (36 – 209 mg/dL in the ezetimibe group
compared with 32 – 202 mg/dL in the statin group).
Among the statin-treated patients, 12 patients experi-
enced an increase in LDL-C level, whereas 3 patients in
the ezetimibe-treated group experienced an increase in
LDL-C level.
In patients grouped by baseline diabetic status (yes/no),
the median percent change from baseline in LDL-C was
numerically greater in patients being treated with
ezetimibe added to statin compared with patients who
doubled their statin dose in both subgroups. In patients
with diabetes, the median percent change± standard devi-
ation (SD) was −22.3% ±23.0 with the combination
therapy vs. -16.1% ±29.5 with doubling the statin dose; and
in patients without diabetes the median percent change±
SD was −30.1% ±17.0 with the combination treatment vs
−7.2% ±20.8 with doubling the statin dose.
A summary of safety is shown in Table 2 for the entire


















Figure 3 Inter-individual variability in response to treatment in Taiwaevents, with 18 events in the ezetimibe group and 16 in
the statin group. A detailed list of adverse events and
serious adverse events in the subset of patients who
experienced adverse events is shown in Table 3. In gen-
eral, the occurrence of specific adverse events was simi-
lar in both treatment groups. Pharyngitis was the most
frequently reported adverse event in the ezetimibe-
added-to-statin group (n = 3 [16.6%]). Vertigo was the
most frequently reported adverse event in the statin group
(n= 3 [18.8%]). There was 1 serious adverse event—an
upper respiratory infection leading to hospitalization in
the ezetimibe group, which was not considered drug-
related by the investigator. There were no clinically mean-
ingful differences in laboratory values between treatment
groups at study end and no deaths occurred during the
study.
Discussion
After 8 weeks of treatment, ezetimibe added to statin
resulted in significantly greater reductions in LDL-C and
total cholesterol. Similar changes occurred in HDL-C
and triglycerides in both treatment groups. The safety
and tolerability profiles were generally similar for both
treatments. These results are consistent with expecta-
tions for these treatment regimens in Caucasian patients


















nese patients with hypercholesterolemia.





Number of adverse events 18 (43) 16 (39)
≥1 adverse event 9 (21) 8 (20)
Serious adverse events 1 (2) 0 (0)
Serious drug-related adverse events 0 (0) 0 (0)
Deaths 0 (0) 0 (0)
Table 3 Frequency and percentage of adverse events in
the subset of patients with at least one adverse event
and serious adverse event by body system, and
COSTART term





Body as a Whole
Fever 1 (5.6) 0
Headache 1 (5.6) 1 (6.3)
Pain back 1 (5.6) 0
Pain chest 1 (5.6) 0
Cardiovascular System
Syncope 0 1 (6.3)
Digestive System
Esophagitis 1 (5.6) 0
Nausea 1 (5.6) 1 (6.3)
Rectal discharge 1 (5.6) 0
Metabolic and Nutritional Disorders
Diabetes mellitus 1 (5.6) 0
Gout 1 (5.6) 0
Nervous System
Anxiety 1 (5.6) 0
Dizziness 2 (11.1) 1 (6.3)
Insomnia 0 1 (6.3)
Vertigo 0 3 (18.8)
Respiratory System
Cough inc 0 1 (6.3)
Pharyngitis 3* (16.6) 1 (6.3)
Rhinitis 0 1 (6.3)
Sputum inc 0 1 (6.3)
Voice altered 0 1 (6.3)
Skin and Appendages
Rash 1 (5.6) 0
Special Senses
Cataract 1 (5.6) 0
Conjunctivitis 1 (5.6) 1 (6.3)
Deaf 0 1 (6.3)
Tinnitus 0 1 (6.3)
* One Serious Adverse Event.
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siderable proportion of patients with dyslipidemia do not
achieve LDL-C treatment targets on moderate dose statin
[33]. Intensifying treatment is recommended. One option is
to increase the dose of the statin until lipid targets are
achieved or until the dose is not tolerated. If this strategy is
not successful, adding a second therapy with a different
mechanism of action to lower lipid levels (e.g., ezetimibe,
fibrates, or niacin) may be the due course of action. In the
Begin with the Real-world Patients of Non-goal-achieved
Hypercholesterolemia in Taiwan through the Ezetimibe/
Simvastatin Tablet (BRAVO) Study (N=173 Taiwanese sub-
jects across all cardiovascular risk categories), 91% of
patients attained NCEP ATP III goals and experienced sig-
nificant reductions in LDL-C, total cholesterol and triglyce-
rides when treated with the combination ezetimibe/simvas-
tatin [34]. Similarly, the results of this trial demonstrated
that the addition of ezetimibe to a moderate dose of a statin
is significantly more effective than doubling the dose of the
statin for reducing LDL-C levels in Taiwanese patients. The
subgroup analysis in diabetic and non-diabetic patients,
although done in a limited number of subjects, is consist-
ent with previous results in Western subjects showing that
ezetimibe added to a statin reduces LDL-C more than
doubling the statin dose in both diabetic and non-diabetic
patients [35,36]. Larger trials in a broader Asian popula-
tion base are warranted to provide appropriate statistical
power and better interpretation of the results.
In addition, more patients achieved LDL-C <100 mg/dL
with ezetimibe added to statin (58.6%) vs doubling the statin
dose (41.2%). This difference was not significant; however,
this may be due to the slightly (although not significantly)
higher baseline LDL-C levels in the ezetimibe add-on
group (143.4 mg/dL) compared with the statin group
(129.8 mg/dL). It has been shown that higher baseline
LDL-C was a significant negative predictor of LDL-C
goal attainment, and this finding is consistent with
the results reported here [33,37]. In addition, the
small numbers of patients in this study provided lim-
ited power to detect statistically significant differences
for the secondary endpoints.
Inter-individual variability in LDL-C lowering has been
reported with both high-potency statins and ezetimibe
[38,39]. It is notable that in this study adding ezetimibereduced LDL-C in all but 3 individuals (26 out of 29
patients) and doubling statin reduced LDL-C in all but
12 individuals (22 out of 34 patients), but the amount of
the decrease varied considerably between individuals.
This finding is consistent with data from another study
that showed variability in reductions in the fraction of
cholesterol absorption with ezetimibe monotherapy, eze-
timibe added to statin, and statin monotherapy [40]. The
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understood.
There is no test currently available that allows clini-
cians the ability to target lipid-lowering treatment ac-
cordingly. The only way to assess if a patient will attain
treatment targets with statin monotherapy is through
use of appropriate potency, dose and duration of statins.
Clinical trial data support a complementary approach
targeting the synthesis and the absorption of cholesterol
to improve the lipid profile of patients who show a poor
response to statin monotherapy [41-43]. More detailed
analyses of patients categorized into specific statin
groups may be of interest but would require a blinded
study with a larger population.
In the present study, similar tolerability profiles were
observed with both treatment regimens. The treatment
group sizes were small and the study was not of suffi-
cient duration to detect the presence of very rare adverse
events. Despite these limitations, the tolerability results
are consistent with expectations for these drugs at the
doses given.
Conclusions
In conclusion, this study demonstrated that ezetimibe
added to ongoing statin therapy resulted in significantly
greater lipid lowering compared with doubling the dose
of statin in Taiwanese patients with hypercholesterol-
emia. Studies to assess clinical outcome benefit are
ongoing.
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